Casein-Derived Tripeptide LLY Potently Blocks ACE Through Multiple Binding Interactions
The casein-derived tripeptide LLY (Leu-Leu-Tyr) showed high ACE-inhibitory activity and stability, with detailed molecular studies revealing multiple binding interactions at the enzyme's active site.
Quick Facts
What This Study Found
The casein-derived tripeptide LLY demonstrated high ACE-inhibitory activity with excellent stability. Systematic investigation revealed the molecular details of LLY-ACE binding interactions important for understanding and designing antihypertensive peptides.
Key Numbers
LLY (Leu-Leu-Tyr) showed high ACE inhibitory activity with specific binding interactions characterized at the molecular level.
How They Did This
ACE-inhibitory peptide LLY isolated from casein hydrolysate. ACE-inhibitory activity and stability tested. LLY-ACE interaction characterized through systematic molecular investigation techniques.
Why This Research Matters
Milk-derived ACE-inhibitory peptides are among the most studied food-derived bioactives. Detailed molecular mapping of how LLY binds ACE advances both the science of food-derived antihypertensives and the rational design of more potent peptide candidates.
The Bigger Picture
Casein-derived peptides like VPP and IPP have already been commercialized in functional foods (Calpis, Evolus). LLY adds to the growing library of validated milk peptides with ACE-inhibitory activity, and the detailed binding data could guide development of next-generation dairy-based antihypertensive products.
What This Study Doesn't Tell Us
In vitro study — ACE inhibition in a test tube doesn't guarantee blood pressure lowering in humans. The specific IC50 value wasn't reported in the available abstract. Bioavailability after actual dairy consumption is unknown.
Questions This Raises
- ?How does LLY's ACE-inhibitory potency compare to the commercialized casein peptides VPP and IPP?
- ?Can LLY survive gastrointestinal digestion and reach the bloodstream at active concentrations?
- ?Would LLY-enriched dairy products lower blood pressure in human clinical trials?
Trust & Context
- Key Stat:
- High ACE inhibition + stability Casein tripeptide LLY combines potent enzyme blocking with structural stability — key requirements for a viable functional food ingredient
- Evidence Grade:
- Preliminary evidence from in vitro enzyme assays and molecular interaction studies. No in vivo or clinical validation.
- Study Age:
- Published in 2024; represents current research in milk-derived ACE-inhibitory peptide characterization.
- Original Title:
- Investigation of the Interaction Between Angiotensin-Converting Enzyme (ACE) and ACE-Inhibitory Tripeptide from Casein.
- Published In:
- International journal of molecular sciences, 25(23) (2024)
- Authors:
- Yang, Cuicui, Xie, Tianzhao, Cai, Mengmeng, Xu, Xiaoting, Li, Muzijun, Liu, Pengru, Lan, Xiongdiao
- Database ID:
- RPEP-09580
Evidence Hierarchy
Frequently Asked Questions
Does drinking milk lower blood pressure?
Some studies suggest regular dairy consumption is associated with modest blood pressure benefits. This study identifies a specific peptide (LLY) from milk protein that blocks the blood-pressure-raising enzyme ACE. However, whether enough LLY is released during normal dairy digestion to meaningfully affect blood pressure hasn't been determined.
How is this different from other milk peptides like VPP and IPP?
VPP and IPP are well-known casein-derived ACE inhibitors already used in commercial products. LLY is a different peptide sequence (Leu-Leu-Tyr) with its own unique binding profile at the ACE active site. This study adds it to the growing catalog of validated dairy antihypertensive peptides.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09580APA
Yang, Cuicui; Xie, Tianzhao; Cai, Mengmeng; Xu, Xiaoting; Li, Muzijun; Liu, Pengru; Lan, Xiongdiao. (2024). Investigation of the Interaction Between Angiotensin-Converting Enzyme (ACE) and ACE-Inhibitory Tripeptide from Casein.. International journal of molecular sciences, 25(23). https://doi.org/10.3390/ijms252313021
MLA
Yang, Cuicui, et al. "Investigation of the Interaction Between Angiotensin-Converting Enzyme (ACE) and ACE-Inhibitory Tripeptide from Casein.." International journal of molecular sciences, 2024. https://doi.org/10.3390/ijms252313021
RethinkPeptides
RethinkPeptides Research Database. "Investigation of the Interaction Between Angiotensin-Convert..." RPEP-09580. Retrieved from https://rethinkpeptides.com/research/yang-2024-investigation-of-the-interaction
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.